ProPhase Labs, Inc. Accrued Royalties, Current
ProPhase Labs, Inc. (PRPH) had Accrued Royalties, Current of $3.50 million as of 2012-12-31, per its 10-Q filed 2013-11-13.
Discontinued › Notes › Accrued Liabilities, Current
us-gaap:AccruedRoyaltiesCurrent · last filed 2015-03-27
- 2012-12-31: Accrued Royalties, Current $3.50M; Accrued Royalties, Current as first filed $0.00.
- 2012-12-20: Accrued Royalties, Current $3.50M.
- 2012-09-30: Accrued Royalties, Current $3.52M.
- 2012-06-30: Accrued Royalties, Current $3.52M.
| Period end | Accrued Royalties, Current | Accrued Royalties, Current as first filed |
|---|---|---|
| 2012-12-31 | $3.50M 10-Q · filed 2013-11-13 | $0.00 10-K · filed 2013-03-28 |
| 2012-12-20 | $3.50M 10-K · filed 2015-03-27 | |
| 2012-09-30 | $3.52M 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $3.52M 10-Q · filed 2012-08-13 | |
| 2012-03-31 | $3.52M 10-Q · filed 2012-05-11 | |
| 2011-12-31 | $3.52M 10-K · filed 2013-03-28 | |
| 2011-09-30 | $3.52M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $3.52M 10-Q · filed 2011-08-12 | |
| 2010-12-31 | $3.52M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |